The Role of Bridging Studies in the Development of Cholinesterase Inhibitors for Alzheimers Disease

ISSN： 1172-7047

Source： CNS Drugs, Vol.10, Iss.5, 1998-11, pp. : 355-364

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomics of Cholinesterase Inhibitors in the Treatment of Alzheimers Disease

By Jönsson L.

PharmacoEconomics, Vol. 21, Iss. 14, 2003-01 ,pp. : 1025-1037

Adis International

Access to resources Recommend Favorite

Novel cholinesterase inhibitors as future effective drugs for the treatment of Alzheimer’s disease

By Martinez Ana Castro Ana

Expert Opinion on Investigational Drugs, Vol. 15, Iss. 1, 2006-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite

Cholinesterase Inhibitors for Alzheimer's Disease

By Grutzendler J. Morris J.C.

Drugs, Vol. 61, Iss. 1, 2001-01 ,pp. : 41-52

Adis International

Access to resources Recommend Favorite

Cholinesterase Inhibitors Used in the Treatment of Alzheimers Disease: The Relationship Between Pharmacological Effects and Clinical Efficacy

By Wilkinson D.G.

Drugs & Aging, Vol. 21, Iss. 7, 2004-01 ,pp. : 453-478

Adis International

Access to resources Recommend Favorite

Drug Persistency of Two Cholinesterase Inhibitors: Rivastigmine versus Donepezil in Elderly Patients with Alzheimers Disease

By Suh Dong-Churl

Drugs & Aging, Vol. 22, Iss. 8, 2005-01 ,pp. : 695-707

Adis International

Access to resources Recommend Favorite